US EditionCentury Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Century Therapeutics Announces Strategic Pipeline Shift and 2024 Financial Results
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) outlined a strategic pipeline re-prioritization and shared its financial results for the year 2024. This move aims to focus on potentially groundbreaking programs while extending the company’s cash runway into the fourth quarter of 2026. Key priorities include advancing four core programs engineered with the company’s proprietary Allo-Evasion™ 5.0 technology. CNTY-308, targeting B-cell…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
